Home: Oncology Leader Commentary: Kathy I. Pritchard, MD

Click on the topic below for comments by Dr Kathy I. Pritchard to comment on. You will also find links to related articles and clinical trials.

First-line trials of adjuvant Arimidex
Mechanism of action of Faslodex
Faslodex intramuscular injection
Faslodex and hot flashes
Faslodex and bone metabolism
Overview data on ovarian ablation
Adjuvant Zoladex
Endocrine effects of adjuvant chemotherapy

Faslodex and hot flashes

Interview with Neil Love, MD from Breast Cancer Update for Medical Oncologists, Program 5 2000

Play Audio Below:

It doesn’t cross the blood-brain-barrier and patients do get hot flashes. If they don’t have estrogen, they will get hot flashes. One of the issues that has been raised is that, because Faslodex completely down regulates all the receptor on tumor, or we believe it does, you could add back low doses of estrogen. They will cross the blood-brain-barrier, they could stop the hot flashes and still not adversely affect the good results of Faslodex on the tumor. And, I think the other area where you could do some adding back is with something like estring or some local form of estrogen in the genitourinary tract, and the potential for doing that in the face of a complete estrogen receptor down regulator, I think, is also a good possibility.

Relevant Links:

Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?
Zand, R. S. R.; Grass, L.; Magklara, A.; Jenkins, D. J. A., and Diamandis, E. P. (Reprint available from: Zand RSR Mt Sinai Hosp, Dept Pathol & Lab Med 600 Univ Ave Toronto ON M5G 1X5 Canada). Breast Cancer Research & Treatment. 60(1):1-8, 2000 Mar.

Selective estrogen receptor modulators: Structure, function, and clinical use [Review].
Osborne, C. K. and Fuqua, S. A. W. Journal of Clinical Oncology. 18(17):3172-3186, 2000 Sep.

Development of a novel, "pure" antiestrogen.
Howell, A.; Osborne, C. K.; Morris, C., and Wakeling, A. E. ICI 182,780 (Faslodex (TM)) -. Cancer. 89(4):817-825, 2000 Aug 15.

Similarities and distinctions in the mode of action of different classes of antioestrogens [Review].
Wakeling, A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract

Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: A brief overview.
Terakawa, N. (Reprint available from: Terakawa N Tottori Univ, Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan).. Oncology. 59(Suppl 1):3-4, 2000. No abstract

Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Smolnikar, K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research & Treatment. 63(3):249-259, 2000 Oct. In process

Symposium overview: Estrogens and antiestrogens in managing the patient with breast cancer.
Newman, L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary, S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX 77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep. In process

Top of Page